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Abstract 
Molecular mechanisms underlying the development and progression of PanNET are still insufficiently 
understood. Efficacy of currently approved PanNET therapies is limited. While novel treatment options 
are being developed, patient stratification permitting more personalized treatment selection in PanNET 
is yet not feasible since no predictive markers are established. The lack of representative in vitro and in 
vivo models as well as the rarity and heterogeneity of PanNET are prevailing reasons for this.  
In this study, we describe an in vitro 3D human primary PanNET culture system as a novel preclinical 
model for more personalized therapy selection. We present a screening platform allowing multi-center 
sample collection and drug screening in 3D cultures of human primary PanNET cells. We demonstrate 
that primary cells isolated from PanNET patients and cultured in vitro form islet-like tumoroids. Islet-
like tumoroids retain the neuroendocrine phenotype and are viable for at least two weeks in culture with 
high success rate (86%). Viability can be monitored continuously allowing for a per-well normalization. 
In a proof-of-concept study, islet-like tumoroids were screened with three clinically approved therapies 
for PanNET: Sunitinib, everolimus and temozolomide. Islet-like tumoroids display varying in vitro 
response profiles to distinct therapeutic regimes. Treatment response of islet-like tumoroids (IC50) 
differs also between patient samples. We believe that the presented human PanNET screening platform 
is suitable for personalized drug testing in a larger patient cohort and a broader application will help in 
identifying novel markers predicting treatment response and in refining PanNET therapy.   
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Introduction 
In contrast to many other malignancies, there are no molecular characteristics and biomarkers supporting 
treatment decisions in pancreatic neuroendocrine tumors (PanNET). While molecular mechanisms 
underlying PanNET development and disease progression are continuously further deciphered [1,2] and 
numbers of clinically approved therapies are steadily rising, the treatment options for PanNET are still 
primarily chosen based on clinician judgement.  
The lack of appropriate models and the rarity of PanNET disease are two major factors that hinder 
further advances in PanNET translational research. Testing more effective therapies as well as 
performing predictive studies are leaping behind. Currently, only a limited number of human PanNET 
cell lines are available – with BON1, QGP1 and CM being the most commonly studied [3–6]. It is 
pertinent to note that while these cell lines were used to experimentally dissect molecular mechanism of 
NETs, they do not represent well-differentiated, slowly proliferating PanNETs. These afore mentioned 
cell lines are highly proliferative and were found to differ fundamentally in their mutational genetic 
background compared to PanNETs. In fact, studies have shown that these cell lines resemble poorly 
differentiated pancreatic neuroendocrine carcinomas (PanNEC) rather than PanNETs [7–11]. Moreover, 
other authors have even questioned the tissue of origin of aforementioned cell lines, raising significant 
debate as to the translational relevance of work performed using these cell lines [11,12]. Recently, 
Benten et al. described NT-3 as a novel cell line that better reflects well-differentiated slow proliferative 
PanNETs, which present the bulk of PanNETs [13]. Nevertheless, the full molecular profile of NT-3 
cells remains to be determined so that its similarity to the primary well-differentiated slow proliferative 
subtype can be established. Moreover, neither available cell lines nor genetically engineered mouse 
models recapitulate the spectrum of different molecular subtypes of human primary PanNETs [2,14]. A 
stronger focus on developing more personalized in vitro models for studying these tumors is therefore 
demanded urgently. Cultivation and expansion of patient derived neuroendocrine cells has been 
challenging owing to their intrinsically poor capacity for in vitro proliferation. However, due to advances 
in cell culture techniques, cell models of well-differentiated slow proliferative PanNET derived from 
primary tissue have recently been used to study drug response and dissecting its underlying molecular 
mechanisms. For example, studies on isolated human primary PanNET cells cultured in vitro indicated 
that such a model might be utilized to determine patient response to treatment [15–18]. However, the 
major limitations of all these studies are the short cultivation window of the cells, the non-physiological 
2D setting with limited cell-cell interactions, as well as their small scale in terms of investigated 
treatments and patient numbers.  
In recent years, there has been tremendous advances in the development of 3D tissue culture techniques, 
including scaffold-free setups in ultra-low attachment plates or scaffold-based encapsulation cultures to 
allow cell growth in three dimension [19–23]. Culture of cells in 3D mimics a more physiological 
architecture of a tumor tissue, including cell-cell contact and allowing the development of spatial 
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differences in the culture system with respect to proliferation, cell death and hypoxia within spheroids 
[21,24–26]. Additionally, cells in 3D can be cultured and treated longer than in 2D monolayer [21]. 
Cells cultured in 3D frequently display increased therapy resistance compared to cells cultured in 2D 
[27–29], where 3D culture most likely better reflects the in vivo situation [30,31]. For this reason, lately 
high-throughput screening of pharmacological compounds preferentially being performed in 3D-
cultured cells [32–34].  
With the presented study, we aimed for developing a platform to collect PanNET samples from multiple 
surgical centers, to isolate primary cells and to cultivate these cells in 3D retaining neuroendocrine tumor 
characteristics, and finally to measure short- and long-term in vitro treatment response.   
6 
 
STAR⁕ METHODS 
KEY RESOURCE TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
ANTIBODIES 
Anti-human-Ki-67  
(1:200) 
Dako M7240 
Anti-human-Synaptophysin 
(1:4000) 
Nococastra 27G12 
Anti-human-Insulin  
(1:100) 
Sigma I-2018 
BIOLOGICAL SAMPLES 
Human pancreatic neuroendocrine 
tumor (PanNET) specimen 
This study NA 
Primary human PanNET cell 
culture 
This study NA 
DEVICES and CONSUMABLES 
Gentle MACS ™ dissociator 
 
Miltenyi Biotec NA 
Cell+coated and TC tested 24-well 
plates 
Sarstedt 83.3922.300 
 
24/96 well Corning® Costar® 
ultra-low attachment plates 
Corning CLS4515 
 
PAXgene Tissue FIX Cotnainer Qiagen 765312 
 
PAXgene Tissue STABILIZER Qiagen 765512 
 
Infinite® 200 PRO plate reader 
 
Tecan NA 
Automated immunostainer  
Bond RX 
Leica Biosystems NA 
Automated Slide Scanner 
panoramic 250 
3DHistech 
 
NA 
CHEMICALS and PEPTIDES 
Recovery Freezing Medium Gibco 
 
12648-010 
Advanced DMEM-F12 Gibco 
 
D6421 
Collagenase IV Worthington LS004188 CLS-4 
 
Trypsin-EDTA (0.25%) Sigma Aldrich T4049 
 
DNase Roche 10104159001 
 
ACK lysis buffer Thermo Fisher A1049201 
 
Epidermal growth factor  
(EGF) 
Thermo Fisher PHG0311 
 
Basal fibroblast growth factor 
(bFGF) 
Thermo Fisher PHG0026 
Placenta Growth Factor  
(PlGF) 
Selleckchem 264-PGB-010 
 
Insulin-like growth factor 1 
(IGF-1) 
Selleckchem 100-11 
Accutase Gibco A11105-01 
 
Growth-factor-reduced Matrigel 
(MTGL) 
Corning 354230 
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Real-Time Glo ™ MT Cell 
Viability Assay  
Promega G9712 
Human plasma Interregional Blood Transfusion 
SRC Epalinges 
92040 
Thrombin Diagnotec 100-125 
 
Sunitinib (S1042) Selleckchem 
 
S1042 
 
Everolimus (S1120) Selleckchem S1120 
 
Temozolomide (S1237) Selleckchem S1237 
 
 
LEAD CONTACT AND MATERIALS AVAILABILITY 
Further information and request for resources and reagents should be directed to and will be fulfilled 
by the Lead Contact Dr. I. Marinoni (Ilaria.marinoni@pathology.unibe.ch). This study did not 
generate new unique reagents.  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Primary cell culture  
Isolated primary PanNET cells were maintained in AdvDMEM+GF medium (DMEM-F12, 5% FBS, 
Hepes 1M, 1% L-Glutamine, 1% penicillin-streptomycin-amphotericin B, 20ng/ml EGF, 10ng/ml 
bFGF (Thermo Fisher, CH), 100ng/ml PlGF, 769ng/ml IGF1 (Selleckchem, USA) and 24-well 
Corning® Costar® ultra-low attachment (ULA) plates (Corning, USA) (500µl/well, 3-5x105 
cells/well) in an cell incubator (21% O2, 5% CO2, 37°C). For drug screen cells were resuspended in 
fresh AdvDMEM+GF medium supplemented with 123µg/ml growth-factor-reduced Matrigel® 
(Corning, USA) and plated in 96-well ULA plates (50µl/well, 3-4x103 cells/well).  
To setup the PanNET screening platform including drug screening, we made use of primary material 
from a total of 16 PanNET patients depicted in Supplementary Table 1. 
 
Patient studies  
All patients agreed on the use of residual material and have signed an institutional informed consent. 
Patient characteristics are shown in Supplementary Table 1. The study was approved by the cantonal 
authorities (Kantonale Ethikkomission Bern, Ref.-Nr. KEK-BE 105/2015) and Italian ethic 
commission (Comitato Etico, CE 252/2019). 
 
METHODS DETAILS 
Patient samples and cryopreservation 
Fresh human PanNET tissue was obtained from patients diagnosed with PanNET undergoing surgery at 
the Inselspital Bern, Switzerland, or at the Pancreatic Surgery Unit, Pancreas Translational & Clinical 
Research Center, San Raffaele Scientific Institute, Milan, Italy. Tumor tissues of 16 PanNET patients 
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were used for 19 isolations, 12 isolations for method establishment, and 7 is isolations for the proof-of-
concept drug screening. Patient characteristics are summarized in Supplementary Table 1.  
Upon surgical resection a pathologist processed one mirror block of the tumor tissue to 8mm3 blocks 
under sterile conditions avoiding necrotic regions. These blocks were suspended in Recovery Cell 
Culture Freezing Medium (Thermo Fisher, CH), cryopreserved using an isopropyl alcohol freezing 
container (Nalgene, USA) and stored in liquid nitrogen. The other mirror block was embedded in a 
micro cassette and fixation was performed with PAXgene Tissue System according manufacturer’s 
instructions. In short, tissue was incubated in PAXgene Tissue FIX Container (Qiagen, GER) at room 
temperature overnight. Fixated tissue was transferred into PAXgene Tissue FIX Container (Qiagen, 
GER) at 4°C until paraffin embedding (1-2 days) or keept at -20°C if embedding was not performed 
instantly. 
 
Primary cell isolation and culture 
For primary cell isolation, tissue was thawed 45-60s in 37°C water bath and cut in 1mm3 pieces and 
washed with medium (advanced DMEM-F12, Hepes 1M, 1% L-Glutamine, 1% penicillin (100U/ml), 
1% streptomycin (0.1mg/ml), 1% amphotericin B (0.25mg/ml) (Merck, CH)) and DPBS (Thermo 
Fisher, CH). After aspiration of the medium, the tissue was incubated in 5ml digestion medium 
(10mg/ml Collagenase IV (Worthington, USA), 0.25% Trypsin-EDTA (Sigma-Aldrich, CH), 10mg/ml 
DNase (Roche, CH) in advanced DMEM-F12, Hepes 1M, 1% L-Glutamine, 1% penicillin, 1% 
streptomycin, 1% amphotericin B) in a gentleMACS™ dissociator (Miltenyi Biotec, CH) for 1 hour at 
37°C (program TDK_1). After digestion, Trypsin was deactivated with AdvDMEM (Advanced DMEM-
F12, 5% FBS, Hepes 1M, 1% L-Glutamine, 1% penicillin-streptomycin-amphotericin B) and cells were 
filtered through a 70µm smart strainer (Miltenyi Biotec, CH) to remove debris of collagen. Red blood 
cells were lysed for 3min with ACK lysis buffer (Thermo Fisher, CH) at room temperature. After 180g 
centrifugation and aspiration of supernatant, the pellet was re-suspended in AdvDMEM+GF medium 
(DMEM-F12, 5% FBS , Hepes 1M, 1% L-Glutamine, 1% penicillin-streptomycin-amphotericin B, 
20ng/ml EGF, 10ng/ml bFGF (Thermo Fisher, CH), 100ng/ml PlGF, 769ng/ml IGF1 (Selleckchem, 
USA)). Cell suspension was plated in 24-well plates (cell+coated and TC tested, Sarstedt, GER) 
followed by a short spin 30s, 200g and incubation for 1h (21% O2, 5% CO2, 37°C) to partially segregate 
fibroblasts by attachment. Supernatant was collected. For single cell dissociation the cell suspension 
was transferred into a 5ml falcon tube and shortly spun down depending on cell/aggregate size. If larges 
aggregates were present cells were spun at 100-200g, if smaller aggregates were present cells were spun 
200-300g. Cell pellet was washed with DPBS and incubated in Accutase (Thermo Fisher, CH) 
supplemented with DNase (10mg/ml) (Thermo Fisher, CH). Cells were carefully dissociated by repeated 
(10-15x) passage through 1ml syringe and 26G 0,45x13mm Microlance™ (BD, CH) until aggregates 
were not visible anymore. Cell number was estimated using a hemocytometer and seeded in 
AdvDMEM+GF medium in 24-well Corning® Costar® ultra low attachment (ULA) plates (Corning, 
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USA) (5x105cells/ml/well). After two days of recovery phase cellular aggregates were collected in 15ml 
falcon tube and differentially centrifuged at 120g for 5min to separate cells and aggregates from 
debris/apoptotic cells. Supernatant was aspirated to remove semi-and non-viable cells. Cells were 
counted and resuspended in fresh AdvDMEM+GF medium supplemented with 123µg/ml growth-factor-
reduced Matrigel® (Corning, USA) and plated in 96-well ULA plates (50µl/well, 3-4x103 cells/well). 
The setup consisted of 6-9 DMSO-positive control wells, 6 no-cell-negative control wells and techincal 
triplicates for each drug concentration.  
 
Viability measurement 
Real-Time Glo MT Cell Viability Assay (RTG) was used to repeatedly monitor cell viability in 3D 
human primary PanNET culture. RTG assay was performed according to manufacturer’s instructions 
and luminescence was measured in an Infinite® 200 PRO plate reader (Tecan, CH). In brief, after three 
days of sphere formation conditioned medium of each well was supplemented with additional 50µl of 
fresh AdvDMEM+GF medium containing Matrigel and 2X Real-Time Glo™ MT Cell Viability Assay 
(RTG) (Promega, CH) assay reagents to a final volume of 100ul. Growth factors and FBS were 
replenished from a concentrate (0.77µl GFs (130x) + 5µl FBS) every 3-4 days in each well using a 
multichannel pipette. A 6h-RTG-baseline before adding drug compounds was recorded for every well 
at day 0 of the drug screen. For calculating the in vitro growth curve, relative luminescence unit (RLU) 
values were normalized to corresponding baselines. For calculating the in vitro drug response RLU 
values were normalized first to corresponding baselines followed by normalization to the DMSO control 
wells of a particular day as described in more details in the paragraph “curve fitting and drug sensitivity 
data”.  
 
Micro-cell-block (MCB) from islet-like tumoroids 
Islet-like tumoroids corresponding to 3-5x104 cells were collected in a 1.5ml Eppendorf tube (either 
directly at day of isolation (D0) or from 6-9 wells of a 96-well ULA plates at the end of a drug screen 
(D15)). Tumoroids were washed with DPBS and pelleted at 350-500g. The supernatant was aspirated 
and the cells resuspended in human plasma derived from whole blood (Interregional Blood Transfusion 
SRC Epalinges, CH) and Thrombin (Diagnotec, CH) (ratio 5:1) followed by 3 min incubation at room 
temperature. The clot was fixed with 4% PFA for 30-60min protected from light. After a DPBS wash 
supernatant was aspirated and cells were incubated in Hematoxylin and DPBS solution (ratio 1:8) on a 
rocker shaker for 10-15min at room temperature. The counterstained clot was transferred to a plastic 
micro-cassette for paraffin embedding. For immunohistochemistry embedded material was cut in 4µm 
thick serial sections followed by deparaffinization, rehydration and antigen retrieval using an automated 
immunostainer (Bond RX, Leica Biosystems, GER). Antigen retrieval was performed for Ki67 (Dako 
M7240) with Tris for 30 minutes at 95°C, insulin (Sigma I-2018) and synaptophysin (Novocastra 
27G12) with Tris for 30 minutes at 100°C. Antibodies were diluted as follows: Ki-67 1:200, insulin 
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1:4000, synaptophysin 1:100. Slides were counterstained with hematoxylin. Scans were acquired with 
an automated slide scanner Panoramic 250 (3DHistech, HU) at 20X magnification. Images were 
acquired using QuPath software [35].  
 
Drug preparation 
Compounds (Sunitinib (S1042), everolimus (S1120) and temozolomide (S1237)) were obtained from 
commercial vendors and stored as stock aliquots at -80°C. A 5-point, 625-fold concentration range 
(FCR) was used for all compounds in order to have enough data points and a sufficient large drug 
concentration window to calculate reliable absolute IC50s [36]. Starting dosage for each compound was 
selected based on IC50 screens in cancer cell lines publicly available online (see Cancerrxgene.org, 
PharmacoDB, Cancer Drug Resistance DB), from literature search and/or from in vitro data from pilot 
human primary cell cultures and/or from PanNET cell lines (QGP1, NT3, BON1).  
 
Curve fitting and drug sensitivity data 
Drug-response curve data consisted of 6-9 DMSO-positive-controls, 6 no-cell-negative-controls, and 
five drug-response points for a 626-FCR. For IC50 calculation RLU values that were derived from RTG 
assay from short-term treatment at day 3 and long-term treatment at day 7 of each well were weighted 
and normalized as the following: RLU values from each 6h-RTG-baseline measurement (RLUx d0) were 
scaled with the overall minimal value of day 0 for each plate (RLUmin. d0) and transferred into a baseline 
weight (RLUx weight) for each well to minimize well-to-well variability: 
 
RLUx weight=
RLUx d0  
RLUmin.d0
        (1) 
 
Each RLU value from day 3 was then accordingly weighted to its baseline weight:  
 
RLUx d3/7 weight=
RLUx d3/7  
RLUx weight
       (2) 
 
The percentage response from weighted RLU was calculated by normalizing each value to no-cell-
negative-control (0%) and DMSO-positive-control (100%) interval. These data points were fitted in a 
4-Parametric-Linear-Regression (4PL) model [34,37] with two constraint Top=100% and Bottom=0% 
to estimate corresponding IC50. IC50 value differences of >4-fold were clustered in strong-responder 
(SR) and weak-responder (WR) groups. In case of an IC50 value >2.5-fold higher than the highest tested 
target-concentration samples were considered as non-responder (NR). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
QuPath Image Analysis 
11 
 
Using QuPath software [35] digital-scanned H&E and Synaptophysin (SYN) tissue sections were first 
preprocessed in the built-in visual stain editor using default settings for estimation of stain vectors to 
improve staining quality. Each tissue section was then superimposed with a 1000µm grid box. In each 
tissue section one representative tile out of the grid box was selected by a cytopathologist (M.T.) as a 
training set. Using a watershed segmentation method, positive and negative cells were automatically 
detected within each representative tile. Two pathologists (M.T., A.P.) then manually reconfirmed 
positive cell detection based on histomorphological features including cellular and nuclear shape, tumor 
cell nest-formation, tumor columns, nuclear "salt and pepper" structure, nuclear and cytoplasmic 
staining intensity. A minimum of ≥1000 cells were selected for each training set and a total of 67 
parameters (including perimeter, circularity, staining OD etc.) were included for training of the random-
trees machine learning classifier. The auto-update tool within QuPath allowed real-time reconfirmation 
of training efficiency/accuracy. This cell detection parameters were applied on the whole tissue slides 
by creating a script which performed automated cell classification/annotation. Detection results were 
extracted from QuPath and imported and analyzed within R.  
Graph Pad Prism (Version 8.2.1) and R statistical environment were used for data analysis and 
visualization in R version 3.6.2 (2019-12-12) Platform: x86_64-w64-mingw32/x64 (64-bit). Attached 
base packages: Grid; stats; graphics; grDevices; utils; datasets; methods; base. Other attached packages: 
[1] scales_1.1.0; [2] MASS_7.3-51.4; [3] reshape2_1.4.3; [4] ConsensusClusterPlus_1.50.0; [5] 
circlize_0.4.8; [6] ComplexHeatmap_2.2.0; [7] RColorBrewer_1.1-2; [8] Rmisc_1.5; [9] plyr_1.8.5; 
[10] lattice_0.20-38; [11] plotrix_3.7-7; [12] cowplot_1.0.0; [13] forcats_0.4.0; [14] stringr_1.4.0; [15] 
dplyr_0.8.3; [16] purrr_0.3.3; [17] tidyr_1.0.0; [18] tibble_2.1.3; [19] ggplot2_3.2.1; [20] 
tidyverse_1.3.0; [21] broom_0.5.3; [22] readr_1.3.1  
 
Hierarchical clustering analysis of drug response profiles 
Using ConsensusClusterPlus pipeline [38] the number and membership of clusters was determined for 
drug response profiles based on patient specific IC50 values of all three drug treatments. Distances were 
calculated using Pearson’s correlation sorted by an agglomerative hierarchical clustering algorithm. 
WardD2 algorithm was used for subsampling and the final consensus matrix was determined by group 
average. 
 
Gene expression analysis 
Mean expression values of growth factor receptors were analysed in publicly available data of 26 
PanNET patients. RNAseq data was downloaded from the ICGC Data Portal (PAEN-AU project). QC, 
mapping/alignment and raw count quantification is described in Scarpa et al. [2]. From RSEM data 
output for our downstream analysis we chose FPKM (fragments per kilobase of exon per million 
fragments mapped) normalization method to account for sequencing depth and gene length for all raw 
read counts. A list of all available growth factor receptor (GFR) was acquired from the UniProt 
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Knowledgebase [39]. Expression values of all targets were transformed into a 0 to 1 scale for each 
patient to allow interpatient comparability. Mean values for each target receptor were then calculated in 
all of the 26 PanNET patients: 
 
Expression value = Mean (Scaled0..1 (FPKM normalized raw counts))  (3) 
 
Chi-Square test and Monte-Carlo simulation  
A χ2-test of independence was conducted among all variables of interest. In order to meet requirements 
for χ2-test statistic and to account for relatively small expected cell frequencies our dataset was 
resampled using a Monte Carlo simulation (replication=1x105) allowing to calculate p-value estimates. 
 
DATA AND CODE AVAILABILITY  
Original RNAseq dataset from human primary PanNET is publicly available at ICGC Data Portal 
(PAEN-AU project). Complete expression data of growth factor receptors is available in supplementary 
data sheet. The code supporting the current study has not been deposited in a public repository because 
analysis code was generated from generic R-packages, but code is available from the corresponding 
author on request.   
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Results 
Cryopreservation allows a multi-center approach  
PanNET tumors are rare, therefore a collaborative network is crucial. Here we propose a novel platform 
for an effective multi-center approach which permits biobanking of cryopreserved PanNET tissues from 
multiple surgical centers by a single central institution which performs primary cell isolation and drug 
testing (Fig. 1A). After tumor resection, half of the specimen was formalin-free PAXgene-fixated and 
paraffin embedded. These so-called mirror blocks served as controls for sample quality and were used 
to pre-assess patient specific PanNET characteristics and tumor cell content in H&E stainings and 
synaptophysin (SYN) immunohistochemistry - a NET biomarker routinely used in clinics for diagnosis 
of PanNET. The other half was immediately cryopreserved in recovery freezing medium and later 
shipped and processed for primary cell isolation and in vitro drug screening. 
Development of a 3D human primary PanNET cell culture model 
Within this study, we performed 19 isolations from samples of 16 PanNET patients. Patient 
characteristics are summarized in Supplementary Table 1. In the first part of the study (12 patients), we 
setup the sampling, isolation and culture conditions. Two additional isolations were used for live-cell-
imaging to observe tumoroid formation. In the proof-of-concept part of the study (7 patients, including 
3 patients that were also included in the method & development cohort) we tested the suitability of the 
setup for in vitro drug screening (Fig. 1B). During method development, we successfully isolated small 
aggregates and single cells from cryopreserved patient material in 73% (8/11) (Supplementary data file 
1). Age, sex, and other clinical parameters such as WHO grade, TNM staging, and Ki67 did not reveal 
significant association to isolation success and/or cellular yield (Supplementary Fig. 1A). 
In three patient samples, isolation did not yield aggregates or single cells, which we attribute to the 
collection of largely acellular fibrotic or necrotic tissue as revealed from H&E stainings of 
corresponding mirror blocks (Supplementary Fig. 1B). Therefore, careful macroscopic selection of 
viable cellular tumor regions is crucial. Upon implementation of SOPs for sampling at the surgical 
centers, we observed strong quality improvements. In two patient samples (P005, P051) yielding 
successful cell isolation we detected overgrowth of fibroblasts after 15 days (Supplementary Fig. 1C). 
This led us to implement a low FBS concentration in the culture medium and to include a partial 
fibroblast reduction step during cell isolation. Thus, cell suspension was plated on coated plastic for 2 
hours followed by gently rinsing for collection of low-adhesive non-stromal cells. Two tumor cell 
extracts (P032x, P033) were negative for synaptophysin IHC stainings on conventional cytospin 
preparations and not hence excluded for further culture. However, a post hoc analysis by a 
cytopathologist (M.T.) revealed that these cells were tumoral cells (Supplementary Fig. 1D). 
Consequently, to assess tumor cell content accurately, we implemented a formalin fixating paraffin 
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embedding (FFPE) technique termed micro-cell-block (MCB). Micro-cell-blocks retain cellular- and 
tumoroid morphology and requires only a low cell number. Micro-cell-blocks at the day of isolation 
(D0) served as an internal quality control to assess successful fibroblast removal and to guide decision 
for continuation of the drug screening pipeline. Micro-cell-blocks at the end of the experiment (D15) 
allowed to quantify tumor cell content (TC) from SYN immunohistochemistry and to reconfirm target 
cell identity on H&E stainings. 
To account for more physiological cell culture conditions a PanNET-specific culture medium was 
developed combining literature and human transcriptomic data from 26 low grade PanNETs [2]. We 
selected growth factors that were frequently reported in PanNET literature [13,15,40] and for which -
except of EGFR- all the target receptors (FGFR1, IGFR1/2, FLT1/VEGFR1, EGFR) were within the 
upper expression quintile (<28/151) of all currently available growth factor receptors and related 
proteins [40] in human PanNET patients (Supplementary Fig. 1A). Additionally, PanNET culture 
medium was supplemented with low percentage of extracellular matrix. Several findings showed 
improved in vitro culture from Matrigel-complementation due to scaffolding support [41–45]. Low 
concentration Matrigel-supplementation stabilized PanNET culture, without leading to a transient 
artificially increased cellular growth as seen with higher supplementation (data not shown).  
Human primary PanNET cells form islet-like tumoroids and retain neuroendocrine phenotype in 
vitro 
After isolation and cell culture refinement we performed life cell imaging in two human PanNET 
samples. We isolated single cells from cryopreserved primary PanNET tissue (B992) and a PanNET 
liver metastasis (B563m). Isolated cells from both patient specimens were viable. Live-cell-imaging for 
12 days revealed that isolated cells formed structures similar to extracted murine islets [46] which we 
hence termed islet-like tumoroids (Supplementary Fig. 2B). Islet-like tumoroids reached a more defined 
round structure after 72h through aggregation and thereafter remained stable in volume (Supplementary 
Fig. 2C, Supplementary Video). Fourteen days after isolation, histomorphology of the islet-like 
tumoroids was examined and compared to corresponding mirror blocks. Islet-like tumoroids from 
primary and metastatic PanNET patient samples retained expression of synaptophysin (SYN), 
confirming that most of the cells consisted of tumor cells with preserved neuroendocrine phenotype 
(Fig. 1C). Furthermore, islet-like tumoroids from B992 expressed insulin as the original tumor tissue. 
The low percentage of Ki-67 positive tumor cells (2%) in vitro matched with the proliferation index 
described in the original tumor tissue (Ki-67 index <2%) (Fig. 1C, top, Supplementary Table 1). 
Similarly, the percentage of proliferating cells was retained in the metastatic PanNET sample (B563m), 
with Ki-67 index of 12% in the original tumor tissues and 15% in cultured cells, respectively (Fig. 1C, 
bottom, Supplementary Table 1).  
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Setting up an in vitro drug screening pipeline for islet-like tumoroids  
After the successful pilot experiment, we sought to implement a pipeline for in vitro drug screening (Fig. 
2A). Following a two-day recovery phase after initial isolation, cells were re-plated from a 24-well 
format into 96-well plates. By this time, the majority of semi- and non-viable cells from isolation had 
segregated from viable cells. As seen in previous live-cell-imaging analysis (Supplementary Fig. 2B+C), 
during 72h incubation in the 96-well plate, cells formed islet-like tumoroids with only minor changes 
thereafter indicating a suitable time point for starting the drug treatment. Growth factors were 
replenished at days D2, D5, D8 and D12 after initial isolation. Due to low cell numbers available from 
PanNET specimen we selected Real-time Glo (RTG) - a metabolic non-lytic assay- as a surrogate of cell 
viability. Pre-treatment 6h-baseline measurements were recorded to normalize on an individual well 
basis and to correct for variability in cell number. Viability of islet-like tumoroids in each well was 
repeatedly (8x) monitored over a time course of 10 days before storing the cell material for further 
downstream analysis.  
PanNET screening pipeline in control conditions 
As a proof-of-concept experiment, we tested the PanNET drug screening pipeline with seven patient 
samples. Tumor cells were successfully isolated in all seven PanNET specimen. Quantification of tumor 
cells in mirror blocks of original tumor tissue showed variable tumor content within tissues and among 
patients (70±18%, n=7) (Supplementary Fig. 3A+B). Yet, assessment of HE stainings and 
synaptophysin immunohistochemistry on micro-cell-blocks at the day of isolation (D0) by a 
cytopathologist (M.T.) reconfirmed successful selection of tumor cells after isolation and fibroblast 
depletion in all samples used for drug screenings (93±15%, n=7) (Supplementary Fig. 3A+B). 
Moreover, successful culture of tumor cells was also reconfirmed in micro-cell-blocks at the end of each 
experiment (D15) (95±11%) (Supplementary Fig. 3A+B). In all patient samples, islet-like tumoroids 
were formed and remained viable in 85% (6/7) for 15 days in culture.  
Following metabolic activity of untreated islet-like tumoroids during 10 days, we observed an 
association between in vitro proliferation and Ki-67 index in original tumor tissue in the majority of 
samples: Metastatic patient sample (B563m) with Ki-67 index of 15% in the original tumor tissue 
displayed a the highest signal increase (3.8-fold), while four patient samples with lower Ki-67 indices 
(P049, P050, P051, B931) signal increased between 1.1 and 1.7-fold (Fig. 2B). In patient sample P044 
this association was weak exhibiting an increase of 1.6-fold despite a Ki-67 index of 18% in the original 
tumor tissue. P040 was the only sample with decreasing signal in untreated condition, hence, long-term 
time points (>72h) from this particular patient sample were not included in further analysis.  
In vitro drug response in Islet-like tumoroids shows distinctive sensitivity profiles 
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To assess whether 3D human primary PanNET culture could be exploited to predict patient drug 
response in vitro, we evaluated the effect of three clinically approved PanNET treatments on cell 
viability [47]. 3D human primary PanNET cultures from seven different patients were screened for 
response to sunitinib (SUN), everolimus (EVE) and temozolomide (TEM). A 5-point, 625-fold drug 
concentration range ensured a sufficient exploratory drug screening window for accurate IC50 
estimation based on mathematical modelling [36]. As starting points IC50’s from publicly available 
databases were interrogated for each drug, followed by pilot assessments of their anti-proliferative effect 
in PanNET cell lines and murine primary cells (data not shown) as well as further literature research. 
Cells were treated for 10 days and viability was repeatedly monitored at eight time points during drug 
screening. Drug response profiles differed clearly among the three standard of care treatments. Dose-
dependent effects of sunitinib (SUN) and everolimus (EVE) were observed in all tested patient samples 
(Fig. 3A, Supplementary Fig. 4A). Interestingly, comparing inter-patient drug responses we detected 
varying treatment sensitivities among patients (Supplementary Fig. 4A). IC50 values determined after 
short-term (72h) treatment displayed two clearly distinct groups within sunitinib treatment and within 
everolimus treatment harboring >4-fold differences in respective IC50 (Fig. 3B). Also consensus 
clustering matrix and hierarchical cluster analysis (k=4) displayed robust response groups for short-term 
(72h) treatments (Fig. 3C): A strong-responder group with samples sensitive to both treatments (P049), 
a group responding either primarily to everolimus (P049, P040, B563m) or to sunitinib (P050, B931, 
P051) -which we termed mixed-response group-, and a weak-responder group including one sample 
insensitive to all treatments (P044). Importantly, in a integrative hierarchical cluster analysis, short-term 
treatment IC50s - for the majority of patients- clustered closely together with long-term treatment IC50s 
emphasizing robustness of the readouts (Supplementary Fig. 4B). Interestingly, in one case (B931) 
differences between short-term and long-term treatment were detected (Supplementary Fig. 4B).   
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Discussion/Conclusion 
Current murine and human cell line models do not accurately represent human well-differentiated slow 
proliferative PanNETs, nor distinct human molecular subtypes, nor inter-patient variability. In this study 
we present a human PanNET screening platform allowing multi-center sample collection of 
cryopreserved patient specimen with a 86% success rate in primary cell isolation and cell culture. 
Isolated cells of well-differentiated slow proliferative PanNET can be cultured in 3D and screened in 
vitro assessing response profiles to standard of care treatments for PanNETs. Since the cell number was 
the major limiting factor, we established protocols that are optimized for minimal amounts of resection 
specimen.  
We present cryopreservation as a solution to make multi-centric studies possible, thereby overcoming 
the issue of the rarity of PanNET samples. While difficult to implement in different centers, this 
generation of “living cell repositories” is promoted as innovative biobanking setting [48], and 
increasingly used in translational research [49]. To account for more physiological conditions, growth 
factor supplementation for our PanNET culture medium was based on a combination of literature 
research [13,15,40], transcriptomic analysis of growth factor receptors, as well as pilot experiments 
testing different growth factor concentrations and combinations. Final PanNET culture medium 
composition was selected according to best retention of viability during the 15-day period to minimize 
selection. This approach is clearly different from classical organoid approaches, where the culture 
medium selects for stem cell-like cells, and where these cells are kept individually e.g. in matrigel in 
order to produce clonal organoids [50,51]. The aim of our presented “tumoroid” model is to in vitro treat 
a similar tumor cell composition as present in the patient. Following this approach we can obtain a 
remarkable success rate of 86%, but we acknowledge that classical organoid models have many other 
advantages such as the potential to intervene mechanistically [52–54]. With a retention of ±70% of 
isolated cells in experiment before the drug screening we believe that selection bias is minimal and that 
we are capable of treating the majority of cells representing the original tumor [55]. Compared to the 
limited number of studies using primary PanNET tissues in 2D culture [15–18], we observe a 
reproducibly extended life span of the isolated cells up to 15 days. Longer experiments would also be 
possible at least in a subgroup of tumors – however - typically we did observe major changes in viability 
already during the first three days of treatment. 
We show that primary cells isolated from PanNET express original tumor characteristics and retain their 
neuroendocrine phenotype after 15 days. Interestingly, isolated cells form islet-like tumoroids in vitro. 
Similarly, non-neoplastic endocrine pancreatic cells are physiologically structured as islets. Kojima et 
al. reviewed the history of abundant findings which revealed that single cell suspension of endocrine 
pancreatic tissue from several species form islets-like structures and reconstitute their original 
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architecture in vitro [56]. Currently, we do not know whether this reflects endocrine specific phenotype 
or an even broader epithelial phenotype.  
With the conditions presented, isolation and culture were successful in 6 out of 7 patients (86%). Only 
one sample (P040) showed a loss viability after 7 days and was excluded from further long-term 
treatment analysis. During 3D culture, all G1 PanNET patient samples expectedly displayed marginal 
growth, whereas metastatic patient sample B563m (Ki-67 index of 15%) showed the highest growth in 
vitro (3.8-fold in 10 days). One G2 sample (P044, Ki-67 index of 18%) exhibited a somewhat lower 
growth of 1.6-fold in 10 days. It seems not surprising to infrequently observe a rather weak association 
of Ki-67 index and in vitro proliferation. Indeed, a clear linear correlation of Ki-67 index to tumor 
growth rate has not been demonstrate clinically, to our knowledge. Biologically, proliferation represents 
only one aspect out of many: We neither have knowledge about different fraction of cell-death within 
our PanNET specimen, nor do we know exact durations of cell-cycles for the isolated cells from 
individual patient specimen. 
In vitro treatment with clinically approved chemotherapeutics for advanced PanNET disease revealed 
overall distinctive response profiles and drug sensitivities based on IC50s. Comparing short-term (72h) 
vs. long-term treatment (7days and 15 days) showed identical results in the majority of samples, 
indicating that this different time windows are potentially of minor importance. However, in one tumor 
(B931) we observed differences between short-term and long-term treatment. While it might not be 
important to use long-term treatment for detecting primary response in sunitinib and everolimus 
treatment, prolonged treatment could be of potential importance for other chemotherapeutics. In our 
series, we do not see a clear response to temozolomide (TEM) in all of the 7 PanNET examined. A 
possible explanation for this is the mechanism of action of TEM which is strongly linked to cellular 
proliferation. Cytotoxicity of TEM is mediated by O6-methylguanine adducts, which can mis-pair with 
thymine during DNA replication. The resulting futile cycles of DNA processing induce cytotoxic 
double-strand DNA breaks that trigger apoptosis [57,58]. Due to the low proliferation rate of our 
samples a time-window of 10 days may be still too short for a detection of measurable effects. In line 
with that, metastatic patient sample (B563m) that proliferated in vitro shows at least a faint response to 
TEM in our screen - even if the IC50 estimation is still far from our tested drug concentration window 
(Supplementary Fig. 4A) and even if the sample has been scored as weak-responder. We can exclude 
non-potency of the chemotherapeutic compound itself since our implemented 625-fold concentration 
window (0.46uM - 288.00uM) covers a sufficiently large drug window tested in PanNET and 
glioblastoma cell lines (data not shown) to eliminate this as a potential bias.  
In other tumor entities it has been shown that ex vivo drug response correlates with patients response in 
primary cell culture approaches similar to our setup (e.g. esophageal adenocarcinoma, breast cancer and 
head and neck squamous cell carcinoma) [59–61] and in patient-derived xenograft models [62,63]. 
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Further studies are needed to evaluate whether the observed in vitro sensitivity will correlate to clinical 
response in PanNET patients as well. To answer this question, first a prolonged clinical follow-up is 
crucial. Secondly, a larger patient cohort will be needed to perform correlation analysis and to have 
enough statistical power. Full clinical follow-up data of all enrolled patients is therefore collected. 
Chemotherapy-specific in vitro treatment duration and concentration range with the highest predictive 
value will be defined by comparison of clinical data with the in vitro drug response. Due to the non-lytic 
approach, the islet-like tumoroids are collected after the experiment and are available for endpoint 
analysis e.g. transcriptomic analysis, as is the original tumor material from patients. The presented 
PanNET screening platform might therefore serve as a basis for developing personalized treatment of 
PanNET patients, performing molecular analysis on the original tissue to be able to potentially detect 
predictive markers. 
We are well aware that the present protocol still bears limitations. It depends on surgical resection 
specimens of PanNET metastases and high stage tumors, however, most of these patients are diagnosed 
via biopsies of liver metastases. With further experience the protocol has the potential being adapted to 
biopsy specimens, however, some biological role must be proven first to ethically justify additional 
biopsies. The composition of growth factors could certainly be refined further, and the culture system is 
still a model missing stromal and inflammatory factors potentially contributing to tumor response. 
In conclusion, we present a 3D human primary PanNET screening platform as a new preclinical model 
which reflects the characteristics of an individual tumor and has the capability to detect differential 
treatment response. Therefore, this model has the potential to pave the way towards more personalized 
medicine for PanNET patients in the future, including better patient stratification and identification of 
novel and experimental treatments. 
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Figure Legends 
Fig. 1. Human primary PanNET cells form islet-like tumoroids and retain their neuroendocrine 
phenotype in vitro 
(A) Schematic representation of human PanNET screening platform. 
(B) Vennpieagramm displaying usage of human PanNET patient material (outer circle) and individual 
patient (inner circle). Success rate for drug screening in PanNET patient material was 86% (6/7). 
Detailed log of cell isolation is provided in Supplementary Data File 1.  
(C) Representative H&E and IHC stainings of islet-like tumoroids from B992 and original primary 
tumor tissue B992 and islet-like tumoroids from B563m and original metastatic tumor tissue from 
B563m (bottom). Cultured cells were formalin-fixed and embedded after 14 days in PanNET culture 
medium. Formalin fixed primary PanNET tissue or cultured cells were stained for H&E, synaptophysin, 
insulin, and Ki-67. IHC slides were counterstained with Hematoxylin. Scale bar = 50µm. 
Fig. 2. 3D human primary PanNET in vitro model for a personalized drug screening platform  
(A) Detailed schematic representation of in vitro 3D drug screening pipeline in human primary PanNET 
cells. GF= Growth factor replenishment, Thin ticks+ Digit=RTG viability assessment, MCB = Micro-
cell-block. 
(B) In vitro growth curve of all screened primary PanNET samples using the metabolic surrogate assay 
Real-time Glo (RTG) in 3D human primary PanNET culture. Cells were cultured in AdvDMEM+GF 
and low percentage of Matrigel in 0.16% DMSO for 10 days. Normalization was calculated based on 
per-well 6-hour-RTG-baseline measurement. Data represent mean ± SEM (n=7, 3 technical replicates). 
Fig. 3. Effect of standard of care pharmacological treatments on cell viability in 3D human 
primary PanNET culture 
(A) Representative in vitro viability curves using the metabolic surrogate assay Real-time Glo (RTG) 
in 3D human primary PanNET culture (P050 treated with 0.16% DMSO (Ctrl) or indicated treatment 
sunitinib (SUN), everolimus (EVE) and temozolomide (TEM) for 10 days. Normalization was 
calculated based on per-well 6-hour-RTG-baseline measurement and corresponding DMSO control of 
the respective day. For all tested compounds a 5-point, 625-fold concentration range was used based 
on vast literature research and in-house in vitro preliminary studies. Data represent mean ± SEM (n=1, 
3 technical replicates).  
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(B) In vitro dose-response curves of screened PanNET patient displaying IC50 for SUN, EVE, TEM 
after short-term (72h) treatment. Treatment responses (mean ± SEM) were fitted into a 4-parameter 
logistic regression model in GraphPad software to calculate absolute IC50. Data represent fitted curve 
mean (n=7). Dotted line = Absolute IC50. 
(C) Heat map comparing absolute IC50s for SUN, EVE, and TEM in 3D human primary PanNET 
culture after short-term (72h) treatment. Heat map was derived using WardD2 clustering method with 
displaying Pearson’s clustering distance using ComplexHeatmap R-package [38]. Color code 
represents scaled IC50 (Z-score) for each drug.  
Supplementary Table 1. Table summarizing clinical information of the primary PanNET patient 
cohort. 
Supplementary Fig. 1. 
(A) Association table showing estimated p-values from χ2-test of independence using Monte Carlo 
simulation. Association was estimated from all variables of interest from all PanNET patients used in 
this study (n=16).  
(B-D) Stainings of formalin fixed paraffin embedded (FFPE) original tumor tissue (H&E, left) and 
micro-cell-blocks (H&E or Synaptophysin, right) of samples derived from necrotic or acellular fibrotic 
tissue (A), samples with fibroblast overgrowth (B), and samples with few target cells (C). HC (SYN, 
left). All stainings were assessed by two pathologists (M.T., A.P.). Scale bar = 250µm and 50µm.  
Supplementary Fig. 2.  
(A) Mean expression values of growth factor receptors in 26 PanNET patients. RNAseq data form 
Scarpa et al. [2] was downloaded from the ICGC Data Portal (PAEN-AU project). FPKM 
normalization method was applied to raw gene counts. A list of all available growth factor receptors 
was acquired from the UniProt Knowledgebase [39]. Complete expression data of growth factor 
receptor is available in Supplementary Data Sheet 1. Data represent mean ± SD (n=26).  
(B) Representative light micrographs of PanNET islet-like tumoroids from primary tumor (B992, left), 
liver metastasis (B563m, right). Isolated cells were cultured in 24-well ultra-low attachment plates 
(ULA) for 14 days. Scale bar = 200µm. 
(C) Representative time points from 12 days live-cell imaging of primary human PanNET (B992). A 
clear formation of islet-like tumoroids can be observed after 72 hours. Snapshots were taken from 
Supplementary Video. Specific time points (hh:mm) are indicated in every image.  
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Supplementary Fig. 3 
(A) IHC staining and quantification of NET specific biomarker Synaptophysin (SYN) in formalin fixed 
paraffin embedded (FFPE) in all screened original tumor tissues (Tissue) and respective micro-cell-
blocks (MCB). Tumor content in original tissue (%) was assessed by a cytopathologist (M.T.) followed 
by building a classifier in QuPath software [35] to automate quantification. MCBs were individually 
analysed by a cytopathologist (M.T.) comparing H&E and SYN staining to estimate tumor content. Data 
represent mean+SD (n=1-2). Scale bar = 100µm (left), 50µm (right).  
(B) Bar graph quantifying percentage of synaptophysin positive (Syn+) cells in original tumor tissue 
(tissue) and 3D human primary PanNET culture at day of isolation (MCB D0) and at 15 days (MCB 
D15), respectively. Data represent mean ± SD (n=7 individual patients). 
Supplementary Fig. 4 
(A) Line graphs of all screened PanNET patients (n=7) displaying IC50 for sunitinib (SUN), everolimus 
(EVE), temozolomide (TEM) 7 days after treatment. Treatment responses were fitted into a 4-parameter 
logistic regression model in GraphPad software to calculate absolute IC50. Data represent mean ± SEM 
(n=1, 3 technical replicates). Dotted line = Absolute IC50. 
(B) Heat map comparing absolute IC50 for SUN, EVE, and TEM in 3D human primary PanNET 
culture at short-term (3 days) and long-term (7 days) drug treatment. Heat map was derived using 
WardD2 clustering method with displaying Pearson’s clustering distance using ComplexHeatmap R-
package. Color code represents scaled IC50 (z-score) for each drug. Vertical dashed line displays k-
value from consensus clustering analysis.  
Supplementary Video 
Upon single cell isolation of sample B992, cells were seeded in a 96-well ULA plate (5000 cells/well). 
After two days of recovery, the plate was transferred to the Cell-IQ® (CM Technologies Oy, Tampere, 
Finland), a fully integrated incubator (37°C, 21% O2, 5% CO2) including an image acquisition system. 
Phase contrast images (20x) were captured with an integrated CDD camera every two hours for a 
duration of 235 hours with pre-defined positions. Images were processed using the Cell-IQ Analyser™ 
Cell Activation (Yokogawa) software.  
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Sex Ki67 Size
[%] [cm]
P005 65 G2 female 3 3 T3 N1 M0 3B pancreas  Insulin Method
B563m 65 G2 male 15 18.1 T4 NA M1 4 liver NF Screen/Method
B586m 48 G2 female 5 2.5 NA NA M1 4 liver NF Method
B719 63 G2 female 5 5.5 T4 NA M1 4 liver NF Method
B849 64 G1 female 1 2.4 T2 N0 M0 2A pancreas  NF Method
B931 46 G2 female 5 2.8 T1 N0 M0 1 pancreas  NF Method
B992 81 G1 female <2 2.3 T1 N0 M0 1 pancreas  NF Method
P030 79 G2 male 7 4 T2 N1 M0 3A pancreas  NF Method
P032x 49 G3 male 25 3.2 T2 N1 M0 3A pancreas  NF Method
P033 67 G2 male 7 3 T2 N1 M0 3A pancreas  NF Method
P035 42 G2 male 4 2.2 T2 N0 M0 2A pancreas  NF Method
P040 55 G2 female 10 2.5 T2 N0 M0 2A pancreas  NF Screen
P044 19 G2 female 18 3,5 T3 N1 M0 3A pancreas  NF Screen
P049 66 G1 female 1 3.5 T2 N0 M0 2A pancreas  NF Screen
P050 58 G1 male <1 2.5 T2 N1 M0 3A pancreas  NF Screen
P051 25 G1 female <1 7.5 T3 N0 M0 2B pancreas  NF Screen/Method
Age Grade [WHO] T N M
TNM-staging 
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